Novavax shares edged higher as retail investors discussed an unconfirmed rumor that Matrix-M, the company’s proprietary adjuvant (immune-response enhancer), has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects. Matrix-M is designed to strengthen and broaden immune responses and is used in globally approved vaccines, including the R21/Matrix-M malaria vaccine. StockTwits users have speculated about potential oncology applications, but Novavax has not announced a related deal or disclosed safety data supporting the rumor. The company has said its partners are conducting experiments across more than 30 areas covering infectious disease and oncology. The discussion came alongside recent business developments: partners received approvals on August 28 for an XFG-adapted version of Nuvaxovid, while Novavax’s high-teens royalty structure on Sanofi’s global Nuvaxovid net sales resumed for 2026 and 2027. Novavax reported second-quarter revenue of $56.7 million on August 6, including a 76% year-over-year increase in product sales tied to Matrix-M adjuvant demand, and raised its 2026 adjusted total revenue framework to $235 million to $275 million. At publication, NVAX was up 0.69% at $10.18, according to Benzinga Pro.